Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.0.1
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 39,205,000 $ 77,404,000
Accounts receivable - trade 111,000 426,000
Settlement receivable - current portion 5,100,000 5,100,000
Investments in debt securities 18,172,000 19,570,000
Inventory 1,986,000 27,000
Prepaid expenses and other current assets 2,922,000 2,070,000
Total Current Assets 67,496,000 104,597,000
Restricted cash 5,940,000 0
Convertible promissory note receivable and accrued interest 1,594,000 1,556,000
Settlement receivable - noncurrent portion 5,100,000 5,100,000
Finance lease right-of-use assets, net of accumulated amortization 109,000 26,111,000
Operating lease right-of-use asset 5,291,000 0
Fixed assets, net of accumulated depreciation 32,881,000 8,628,000
Intangible assets, net of accumulated amortization 5,041,000 952,000
Investments in equity security - at cost 1,760,000 0
Prepaid expenses - noncurrent 1,195,000 0
Security deposits 41,000 24,000
Total Assets 126,448,000 146,968,000
Current liabilities:    
Accounts payable 2,739,000 2,254,000
Accrued expenses (related party of $0 and $701 as of December 31, 2021, and June 30, 2021, respectively) 2,842,000 3,001,000
Acquisition Payable 2,500,000 0
Finance lease obligations - current portion 45,000 367,000
Operating lease obligation - current portion 160,000 0
Note payable - PPP loan - current portion 0 600,000
Contract liabilities (or deferred revenue) 60,000 423,000
Total Current Liabilities 8,346,000 6,645,000
Finance lease obligations - net of current portion 51,000 31,755,000
Operating lease obligation - net of current portion 5,400,000 0
Term note payable - net of deferred financing costs 22,053,000 0
Total Liabilities 35,850,000 38,400,000
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2021, and June 30, 2021; 218,060,597 and 217,873,094 shares issued and outstanding as of December 31, 2021 and June 30, 2021, respectively 218,000 217,000
Additional paid-in capital 284,957,000 282,058,000
Accumulated other comprehensive loss (91,000) (63,000)
Accumulated deficit (194,486,000) (173,627,000)
Total iBio, Inc. Stockholders' Equity 90,598,000 108,585,000
Noncontrolling interest 0 (17,000)
Total Equity 90,598,000 108,568,000
Total Liabilities and Equity $ 126,448,000 $ 146,968,000